Claim CPD/CME points Click here for more info. ASA = American Society of Anesthesiologists; CI = confidence interval; CVA = cerebrovascular accident; FiO2 = fraction of inspired oxygen; FRC = functional residual capacity; GA = general anaesthesia; IRR = incidence rate ratio; IV = intravenous; LMA = laryngeal mask airway; MOCA = Montreal Cognitive Assessment; NRS = Numerical Rating Scale; PCA = patient-controlled analgesia; PONV = post-operative nausea and vomiting; PPV = positive pressure ventilation; RCT = randomised controlled trial; TCI = target-controlled infusion; TIVA = total intravenous anaesthesia; US = ultrasound.
Authors: Grape S et al. Summary: The hypothesis that the retroclavicular approach, when compared with the supraclavicular approach, would increase the success rate of regional anaesthesia for upper limb surgery was tested in this randomised, controlled single-blinded trial involving 120 twenty ASA physical status 1-3 patients. Using a single-injection technique without needle tip repositioning, patients received either an ultrasoundguided retroclavicular or supraclavicular brachial plexus block with 30 mL of a 1:1 mixture of mepivacaine 1% and ropivacaine 0.5%. Block success rates 30 min after local anaesthetic injection (primary endpoint), defined as a composite score of 14 of 16 points, inclusive of sensory and motor components, were 98.3% (95% CI 90.8-99.9%) in the supraclavicular group and 98.3% (95% CI 90.9-99.9%) in the retroclavicular group (p = 0.99). Mean needling time (secondary outcome) was shortened for the supraclavicular group compared with the retroclavicular group (5 min vs 6.0 min; p = 0.006). Other secondary outcomes including mean time to first opioid request, oxycodone consumption, and pain scores (numeric rating scale, 0-10) at 24 hours postoperatively were similar between the supraclavicular and retroclavicular groups; 439 min vs 447 min (p = 0.19), 10.0 mg vs 7.9 mg (p = 0.80) and 1.2 vs 1.5 (p = 0.09), respectively.
Comment: (Dr Tommy Tseng) The retroclavicular brachial plexus block is a novel approach described in recent years, with increasing interest into it's efficacy as a viable alternative to current accepted approaches. In this study, the authors compared ultrasound-guided retroclavicular and supraclavicular brachial plexus blocks as regional anaesthesia for elective forearm or hand surgery. Patients were placed in a semi-sitting position, with ipsilateral arm adducted. Primary outcome was block success rate 30 min after local anaesthetic injection, with a successful block deemed by a pre-defined composite score of sensory and motor testing of related dermatomes/myotomes. Success rates were 98.3% (95% CI 90.8-99.9%) and 98.3% (95% CI 90.9-99.9%) in the supraclavicular and retroclavicular groups, respectively (p = 0.99), with no statistically significant difference observed between the groups based on this primary outcome. Secondary outcomes, which included block-related and pain-related outcomes, were also similar, with statistically different outcomes only noted in a subset of measured block-related outcomes -being needling time, procedure time, and duration of motor blockade (with comment that these times had minimal clinical relevance). Although results are promising, the retroclavicular approach is without identified disadvantages. Visualisation of the needle path behind the clavicle has been noted to not be possible due to the acoustic shadow created, placing neurovascular structures at risk of being punctured. In this article, two patients in the retroclavicular group were observed to have a vascular puncture, compared to none in the supraclavicular group (p = 0.16). Concerns have also been raised with regards to ineffective block of musculocutaneous nerves -although this was not seen in this article. Overall, it remains to be seen whether the retroclavicular approach can become a suitable alternative to currently accepted practices. So far, there has been research indicating it may be a viable alternative compared to other infraclavicular approaches. It will be intriguing to see what develops in this space.
Reference: Br J Anaesth. 2019; 122(4):518-24 Abstract Chronic use of tramadol after acute pain episode: cohort study Authors: Thiels CA et al.
Summary:
The risk of prolonged opioid use in patients receiving tramadol compared with other short-acting opioids was investigated in this observational study of data from the United States commercial and Medicare Advantage insurance claims database (OptumLabs Data Warehouse) on opioid-naive patients undergoing elective surgery between January 1, 2009 and June 30, 2018. Among 444,764 patients who met the inclusion criteria, 357, 884 filled a discharge prescription for one or more opioids; hydrocodone was the most commonly prescribed post-surgery opioid (53.0% of those filling a single opioid), followed by short-acting oxycodone (37.5%) and tramadol (4.0%). The unadjusted risk of prolonged opioid use after surgery was 7.1% (n = 31,431) with additional opioid use (defined as at least one opioid fill 90-180 days after surgery), 1.0% (n = 4457) with persistent opioid use (any span of opioid use starting in the 180 days after surgery and lasting ≥90 days), and 0.5% (n = 2027) meeting the CONSORT definition (an opioid use episode starting in the 180 days after surgery that spans ≥90 days and includes either ≥10 opioid fills or ≥120 days' supply of opioids). A 6% increase in the risk of additional opioid use was seen in patients receiving tramadol alone compared with those receiving other short-acting opioids (95% CI 1.00-1.13; risk difference 0.5 percentage points; p = 0.049), a 47% increase in the adjusted risk of persistent opioid use (95% CI 1.25-1.69; risk difference 0.5 percentage points; p < 0.001), and a 41% increase in the adjusted risk of a CONSORT chronic opioid use episode (95% CI 1.08-1.75; 0.2 percentage points; p = 0.013).
Comment: (Dr Matthew Bright) The misuse of and addiction to opioids is a serious crisis that affects the social and economic welfare with an estimated cost in the United States of more than $500 billion. There have been a number of strategies employed to reduce the transition to chronic opioid use, including the increasing use of tramadol. This retrospective observational study investigated the prolonged use of tramadol compared with other short-acting opiates in 444,764 opioid-naïve individuals undergoing an elective procedure. Data were collected through 'Medicare' insurance for procedures and post-operative analgesia claims. Opioid use post-operatively was split into additional use (90-180 days), persistent use (>180 days) and the CONSORT definition for heavy opioid use >180 days. There were 357,884 discharge scripts filled for one or more opioids, including a short-acting opioid (74.9%), tramadol alone (3.0%) and tramadol with another short-acting opioid (1.2%). Tramadol was found to have a similar or greater risk of patients transitioning to prolonged use compared with other short-acting opioids. Despite the low rate of tramadol prescription in this study, its use post-operatively is only increasing, likely due to the perceived benefits of being a safer, less addictive short-acting opioid. In patients with additional opioid use from 90-180 days post-operatively, nearly two-thirds of them had no ongoing opioid use in the 30-90 days post-procedure. The additional use of opioids may be explained by patient's use of remaining post-operative opioids for pain unrelated to their initial procedure. The authors suggest that there may also be pharmacologic and neural mechanisms for misuse due to the variable metabolism of tramadol into an active metabolite (desmetramadol), which partly contributes to the opioid effect. Irrespective of opioid choice, larger discharge prescriptions (using morphine milligram equivalents) were associated with a higher unadjusted risk of prolonged opioid use across all 3 definitions of prolonged use. The choice of analgesia post-operatively remains dependent on patient/peri-operative factors and prescriber preference. Simple measures to reduce the rate of prolonged opioid use are still essential and include patient education, limiting the number of pills prescribed, maximising multi-modal analgesia, and non-opioid-based pain control.
PBS Information:
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Reference: Eur J Anaesthesiol. 2-19;36(6):436-41 Abstract
A multicentre randomised controlled trial of the effect of intra-operative dexmedetomidine on cognitive decline after surgery Authors: Cheng XQ et al. Summary: A multicentre prospective RCT examining the effect on cognition of dexmedetomidine at multiple time points up to 6 months post-operatively. It also examined the association with changes in serum concentrations of brain-derived neurotrophic factor (BDNF). A total of 535 patients ≥65 years old who were undergoing scheduled gastrointestinal laparotomy were included. 269 patients in the treatment group received dexmedetomidine 0.5 µg/kg bolus and 0.4 µg/kg/hr infusion, while 266 patients received placebo. Dexmedetomidine was shown to statistically significantly reduce the rate of cognitive decline on post-operative day 3 (40/269 vs 65/266; p = 0.006), on post-operative day 7 (31/269 vs 49/266; p = 0.03) and at 1 month post-operatively (42/250 vs 61/248; p = 0.04). There were also statistically significant changes in BDNF concentrations on the third and seventh post-operative days associated with cognitive impairment at 7 days post-operatively; area under the receiver operating characteristic curve 0.63; p < 0.001 and 0.58; p = 0.016, respectively.
Comment: (Dr Keil Auer) This was a multicentre trial utilising 10 sites across China between 2014 and 2017. The study expanded on previous research demonstrating a link between dexmedetomidine use and decreased rates of post-operative cognitive dysfunction (POCD). This was demonstrated at 7 days post-operatively (primary endpoint) and up to 1 month post-operatively, however, no difference was seen at 3 and 6 months post operatively. Specifically, the cognitive assessment tests showed that dexmedetomidine decreased post-operative impairment of attention. Other positive findings in the trial included decreased rates of delirium in recovery (5% vs 10%; p = 0.03), CVAs (1% vs 3%; p = 0.04) and new arrhythmias (3% vs 7%; p = 0.02). However, given that 20 secondary endpoints were assessed, there is a significant risk of false positives when adhering to a p-value cut-off of 0.05. Failure of previous similar studies to show a decrease in CVAs and pneumonia rates further suggests these may be false positives. A correlation between dexmedetomidine use, BDNF and postoperative cognitive dysfunction was also demonstrated. The authors postulate that the improvement in POCD associated with dexmedetomidine use may be secondary to its effect on BDNF. Strengths of this trial included appropriate exclusion criteria, a reasonable sample size and uniform anaesthetic and post-operative analgesic and antiemetic protocols. The protocol uniformity helped to minimise confounding. Potential weaknesses included numerous secondary endpoints without adjusting p-value cut-offs, narrow inclusion criteria limiting external validity (age ≥65, having elective laparotomy, and MOCA >20) and high loss to follow-up rates (20%). This trial supports current evidence that dexmedetomidine use in certain patient populations may decrease delirium and short-term POCD.
Reference: Anaesthesia 2019;74(6):741-50 Abstract
Multicentre, prospective, double-blind, randomised controlled clinical trial comparing different non-opioid analgesic combinations with morphine for postoperative analgesia: the OCTOPUS study Authors: Beloeil H et al.
Summary/Comment: (Dr Kate Taylor) Over the past two decades, there has been an unprecedented global increase in prescribed opioid use, misuse and opioid-related harms. In light of this crisis, anaesthetists are seeking alternative analgesic strategies to provide safe, balanced pain control in patients. This multicentre, randomised, double-blind controlled trial involving 237 patients undergoing a major surgical procedure, compared the morphine-sparing effects of different combinations of 3 IV non-opioid analgesics (NOA); paracetamol (P), nefopam (N) and ketoprofen (K) post-operatively. Participants were assigned randomly to one of eight groups; control (C) received saline as placebo, P, N, K, PN, PK, NK, and PNK; in the first 48 post-operative hours, these agents were administered 4 times per day. Morphine was used as a rescue medication only when a patient's pain score was greater than or equal to 3/10. The results indicate a combination of all 3 NOAs with morphine results in significant morphine sparing for 48 hours post-operation and is associated with superior analgesia for 24 hours post-operation when compared with morphine alone (PNK group median 24-hour morphine consumption 5 mg vs controls 27 mg, and vs N group 21 mg, all p < 0.05).
However, an inadequate sample size limits the power of this study to draw conclusions. During the collection of data for this study, pain management changed significantly across the 10 study centres as ketamine and lidocaine infusions were more frequently used intraoperatively. Consequently, further research is needed to define optimal post-operative NOAs and opioid combinations in conjunction with intraoperative infusions of ketamine and lidocaine. The incidence of morphine-related side effects in these differing combinations should also be evaluated. This study is important because it produces a novel approach toward attaining analgesia with non-addictive medication, which may also have a potential treatment alternative for persons addicted to opioids.
Reference: Br J Anaesth. 2019; 122(6) The effect of erector spinae plane block on respiratory and analgesic outcomes in multiple rib fractures: a retrospective cohort study Authors: Adhikary SD et al. Summary: Through a retrospective review of electronic medical records, the effectiveness of the erector spinae plane (ESP) block was examined in 79 patients with multiple rib fractures. The primary outcome measures were incentive spirometry volume, maximum numerical rating scale for static pain scores, 12-hour opioid consumption in intravenous morphine equivalent, and mean arterial blood pressure. These outcomes were examined pre and post block for up to 72 hours after blockade; 77% of patients received continuous ESP block for a mean of 3.7 days. There were improvements in incentive spirometry volumes from a mean of 784 mL to 1375 mL (p < 0.01) during the first 24 hours following ESP blockade. Maximum NRS static pain scores were reduced from an average 7.7 to 4.7 in the first 3 hours (p < 0.01). Reductions in opioid consumption did not achieve statistical significance. Overall, the improvements in outcome measures were largely sustained for 72 hours.
Comment: (Dr Tegan Burgess) To date, there has been much excitement over the ESP block, with very little in the way of high-level evidence. This is particularly the case for the use of the ESP in the treatment of rib fractures, where over time, common practice has moved away from thoracic epidurals, first to paravertebral blocks, and now is trending towards the ESP. This is the first article to quantify the efficacy of the block in this area and does so by examining the electronic medical records of 79 patients who were admitted to a level 1 trauma hospital from Jan 2016 to July 2017. It is assumed all patients who received such a block, (single shot or continuous catheter infusion) over this period were included, as no specific exclusion criteria is reported. The intervention was performed by one of six specialist anaesthetists as part of a dedicated regional anaesthesia service. The initial load was 20 mL 0.5% ropivacaine and if a catheter was placed, an ongoing infusion was prescribed with 0.2% ropivacaine at 6-10 mL/hr. The patients were prescribed simple analgesia as well as opioids as necessary. For the first 24 hours following erector spinae plane blockade, there was a mean increase in incentive spirometry volumes of 545 mL (95% CI 319-770). Improvements were sustained for up to 72 hours. Maximum NRS pain scores were significantly reduced from baseline following erector spinae plane blockade. The maximal reduction was in the first 3 hours (39%), with a gradual rise after this point. This suggests the initial bolus (at higher concentration and higher volume) was more effective than the subsequent infusion prescribed. Mean arterial blood pressure did not significantly change from baseline, supporting the anecdotal reports that the ESP is a very haemodynamically stable block. There were no complications related to the block including on insertion and removal, and no patients required escalation in respiratory support following erector spinae plane blockade. Four elderly patients (>80 yrs) died within 2 weeks of receiving the ESP and were reported to have suffered multisystem trauma (no further analysis or comment was provided regarding these deaths). Important conclusions in addition to the above were drawn by the authors. After the first 8 months, where 72% only received a single shot ESP block, the standard practice was moved to all patients receiving ongoing infusions via catheters. This seems common sense, as the pain from rib fractures does not subside after 24 hours. Further, after the conclusion of the study the authors' practice has changed to prescribe an ongoing regime of a bolus of 25 mL every 3 hours (rather than the 6-10 mL/hr infusion studied in the analysis). This supports both anecdotal and published evidence that fascial plane blocks require a relatively large volume in order to spread sufficiently to cover target nerves. It will be interesting to see if the authors again analyse the outcome measures of interest in this study after a period of using this new ongoing prescription. The authors conclude that ESP blocks were associated with improved inspiratory capacity and analgesic outcomes following rib fracture, without haemodynamic instability. Importantly, their final conclusion is that ESP blocks "should be considered to be a viable alternative to other regional analgesic techniques when these are not feasible". This last innocuous statement reminds us that although this study has proven some efficacy and safety of the ESP, no one has yet compared it to previously established standards of paravertebral blocks or thoracic epidurals. Overall, this is a well-constructed retrospective cohort study and the authors are to be commended on providing the first piece of evidence (beyond case reports) to demonstrate the efficacy and haemodynamic stability of the ESP in treating patients with rib fractures. Comment: (Dr Scott Popham) This study examines the application of HFNC (a reasonably new addition to an anaesthetist's armamentarium) in a specific and challenging patient population, undergoing a common procedure, making this study relevant to all anaesthetists. The authors acknowledge that work done with HFNC in the paediatric population demonstrates the ability to overcome upper airway collapse, and that this didn't translate in this study to the morbidly obese having sedation in the left lateral position. Airway obstruction in this patient population is a consequence of relaxation of the skeletal muscles, which normally hold forward the tongue and splint open the pharynx, resulting in a Starling resistor effect. Obstruction was only managed when desaturation in these patients reached <90%, by airway manoeuvres, adjuncts, PPV and/or alteration of propofol infusion rate. Use of these interventions wasn't permitted until the desaturation event had occurred. The most common airway interventions were chin lift, jaw thrust and nasal airway (similar in both groups). The patients had oxygen applied for 5 minutes prior to sedation commencement in both groups, permitting wash-in of supplementary oxygen to the FRC to act as an oxygen reservoir. The sedation technique was standardised, involving solely lidocaine and propofol, although the Appendix containing the details is inaccessible. All patients spontaneously ventilated during the procedure as evidenced by end-tidal CO 2 measurements. It is presumed that obstruction was the cause of hypoxaemia. It wasn't clear whether these were diagnostic or interventional colonoscopies. Often the degree of obstruction correlates to how easily the proceduralist is able to snare polyps -this could have been another secondary measure, since in clinical practice there is often a request for "less diaphragmatic movement" in this patient population, most easily rectified by insertion of an oropharyngeal airway. This is a useful and well-conducted study in that it compared HFNC to a standard, and minimised variables between the two groups. Limitations of the study: the authors did not analyse: a) desaturation events associated with type of anaesthesia provider; b) proceduralist satisfaction with operating conditions; c) whether the interventions were diagnostic or interventional colonoscopies; d) oral airway wasn't documented as an intervention for any of the patients who desaturated; and e) it is unclear whether dosing of lidocaine and propofol as an infusion was in mL/h or TCI. Obstructed breathing, especially in obese patients, tends to result in a seesaw pattern of breathing that makes snaring polyps more challenging. Future research could examine whether different HFNC settings or different techniques to overcome obstruction reduce desaturation events in this patient population.
